title: [Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis].
abstract: Lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS) and erectile dysfunction (ED) are common conditions seen in aging males. Although the exact mechanism of ED combined BPH/LUTS is unknown, treatment with α-adrenergic receptor resistance agents (α-ARAs) contributes to some improvement in ED, and phosphodiesterase-5 inhibitors (PDE-5I) are also of benefit to BPH/LUTS. The action mechanisms of these medications support these observed benefits, which are being studied in the basic science and clinical settings. Much remains to be investigated, but it is clear that the associations between BPH/LUTS and ED lay the foundation for future therapies and possible preventative strategies. This article has mainly summarized the advancement of epidemiology, basic research and treatment of ED combined with BPH/LUTS with α-receptor blockers and phosphodiesterase-5 inhibitors.
authors.affiliation: Andrology Center, Peking University First Hospital, Beijing 100034, China.
authors.forename: Zhe
authors.initials: Z
authors.lastname: Jin
authors.forename: Zhong-cheng
authors.initials: ZC
authors.lastname: Xin
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000328:Adult; D007172:Erectile Dysfunction / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists; D058986:Phosphodiesterase 5 Inhibitors